1	HIV-1	HIV-1	_	_	_	_	_	_	_
2	reactivation	reactivation	_	_	_	_	_	_	_
3	in	in	_	_	_	_	_	_	_
4	resting	rest	_	_	_	_	_	_	_
5	peripheral	peripheral	_	_	_	_	_	_	_
6	blood	blood	_	_	_	_	_	_	_
7	mononuclear	mononuclear	_	_	_	_	_	_	_
8	cells	cell	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	infected	infected	_	_	_	_	_	_	_
11	adults	adult	_	_	_	_	_	_	_
12	upon	upon	_	_	_	_	_	_	_
13	in	in	_	_	_	_	_	_	_
14	vitro	vitro	_	_	_	_	_	_	_
15	CD4	cd4	_	_	_	_	_	_	_
16	cross-linking	cross-linking	_	_	_	_	_	_	_
17	by	by	_	_	_	_	_	_	_
18	ligands	ligand	_	_	_	_	_	_	_
19	of	of	_	_	_	_	_	_	_
20	the	the	_	_	_	_	_	_	_
21	CDR2-loop	cdr2-loop	_	_	_	_	_	_	_
22	in	in	_	_	_	_	_	_	_
23	extracellular	extracellular	_	_	_	_	_	_	_
24	domain	domain	_	_	_	_	_	_	_
25	1	1	_	_	_	_	_	_	_
26	.	.	_	_	_	_	_	_	_

1	HIV-1	HIV-1	_	_	_	_	_	_	_
2	infects	infect	_	_	_	_	_	_	_
3	resting	rest	_	_	_	_	_	_	_
4	peripheral	peripheral	_	_	_	_	_	_	_
5	blood	blood	_	_	_	_	_	_	_
6	mononuclear	mononuclear	_	_	_	_	_	_	_
7	cells	cell	_	_	_	_	_	_	_
8	(	(	_	_	_	_	_	_	_
9	PBMCs	PBMC	_	_	_	_	_	_	_
10	)	)	_	_	_	_	_	_	_
11	but	but	_	_	_	_	_	_	_
12	remains	remain	_	_	_	_	_	_	_
13	inactive	inactive	_	_	_	_	_	_	_
14	state	state	_	_	_	_	_	_	_
15	until	until	_	_	_	_	_	_	_
16	subsequent	subsequent	_	_	_	_	_	_	_
17	cell	cell	_	_	_	_	_	_	_
18	activation	activation	_	_	_	_	_	_	_
19	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	have	have	_	_	_	_	_	_	_
3	demonstrated	demonstrate	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	cross-linking	cross-linking	_	_	_	_	_	_	_
7	of	of	_	_	_	_	_	_	_
8	cell	cell	_	_	_	_	_	_	_
9	surface	surface	_	_	_	_	_	_	_
10	CD4	cd4	_	_	_	_	_	_	_
11	by	by	_	_	_	_	_	_	_
12	gp120-anti-gp120	gp120-anti-gp120	_	_	_	_	_	_	_
13	immune	immune	_	_	_	_	_	_	_
14	complexes	complex	_	_	_	_	_	_	_
15	or	or	_	_	_	_	_	_	_
16	heat-inactivated	heat-inactivated	_	_	_	_	_	_	_
17	HIV-1	HIV-1	_	_	_	_	_	_	_
18	(	(	_	_	_	_	_	_	_
19	iHIV-1	ihiv-1	_	_	_	_	_	_	_
20	)	)	_	_	_	_	_	_	_
21	is	be	_	_	_	_	_	_	_
22	sufficient	sufficient	_	_	_	_	_	_	_
23	to	to	_	_	_	_	_	_	_
24	trigger	trigger	_	_	_	_	_	_	_
25	activation	activation	_	_	_	_	_	_	_
26	signals	signal	_	_	_	_	_	_	_
27	leading	lead	_	_	_	_	_	_	_
28	to	to	_	_	_	_	_	_	_
29	virus	virus	_	_	_	_	_	_	_
30	reactivation	reactivation	_	_	_	_	_	_	_
31	(	(	_	_	_	_	_	_	_
32	9	9	_	_	_	_	_	_	_
33	)	)	_	_	_	_	_	_	_
34	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	this	this	_	_	_	_	_	_	_
3	study	study	_	_	_	_	_	_	_
4	,	,	_	_	_	_	_	_	_
5	we	we	_	_	_	_	_	_	_
6	demonstrate	demonstrate	_	_	_	_	_	_	_
7	that	that	_	_	_	_	_	_	_
8	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
9	nuclear	nuclear	_	_	_	_	_	_	_
10	translocation	translocation	_	_	_	_	_	_	_
11	and	and	_	_	_	_	_	_	_
12	stimulation	stimulation	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	virus	virus	_	_	_	_	_	_	_
15	production	production	_	_	_	_	_	_	_
16	by	by	_	_	_	_	_	_	_
17	iHIV-1	ihiv-1	_	_	_	_	_	_	_
18	were	be	_	_	_	_	_	_	_
19	strictly	strictly	_	_	_	_	_	_	_
20	linked	link	_	_	_	_	_	_	_
21	to	to	_	_	_	_	_	_	_
22	the	the	_	_	_	_	_	_	_
23	concentrations	concentration	_	_	_	_	_	_	_
24	of	of	_	_	_	_	_	_	_
25	viral	viral	_	_	_	_	_	_	_
26	proteins	protein	_	_	_	_	_	_	_
27	used	use	_	_	_	_	_	_	_
28	as	as	_	_	_	_	_	_	_
29	exogenous	exogenous	_	_	_	_	_	_	_
30	stimuli	stimulus	_	_	_	_	_	_	_
31	.	.	_	_	_	_	_	_	_

1	Moreover	moreover	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	we	we	_	_	_	_	_	_	_
4	further	further	_	_	_	_	_	_	_
5	investigated	investigate	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	physiologic	physiologic	_	_	_	_	_	_	_
8	relevance	relevance	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	these	these	_	_	_	_	_	_	_
11	observations	observation	_	_	_	_	_	_	_
12	.	.	_	_	_	_	_	_	_

1	When	when	_	_	_	_	_	_	_
2	submitted	submit	_	_	_	_	_	_	_
3	to	to	_	_	_	_	_	_	_
4	an	an	_	_	_	_	_	_	_
5	in	in	_	_	_	_	_	_	_
6	vitro	vitro	_	_	_	_	_	_	_
7	CD4	cd4	_	_	_	_	_	_	_
8	cross-linking	cross-linking	_	_	_	_	_	_	_
9	by	by	_	_	_	_	_	_	_
10	iHIV-1	ihiv-1	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	PBMCs	pbmc	_	_	_	_	_	_	_
13	from	from	_	_	_	_	_	_	_
14	HIV-1-infected	hiv-1-infected	_	_	_	_	_	_	_
15	patients	patient	_	_	_	_	_	_	_
16	were	be	_	_	_	_	_	_	_
17	found	find	_	_	_	_	_	_	_
18	to	to	_	_	_	_	_	_	_
19	produce	produce	_	_	_	_	_	_	_
20	virus	virus	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	viral	viral	_	_	_	_	_	_	_
3	reactivation	reactivation	_	_	_	_	_	_	_
4	was	be	_	_	_	_	_	_	_
5	associated	associate	_	_	_	_	_	_	_
6	with	with	_	_	_	_	_	_	_
7	increased	increase	_	_	_	_	_	_	_
8	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
9	nuclear	nuclear	_	_	_	_	_	_	_
10	translocation	translocation	_	_	_	_	_	_	_
11	in	in	_	_	_	_	_	_	_
12	patients	patient	_	_	_	_	_	_	_
13	â€™	'	_	_	_	_	_	_	_
14	PBMCs	pbmc	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	Additionally	additionally	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	virus	virus	_	_	_	_	_	_	_
4	reactivation	reactivation	_	_	_	_	_	_	_
5	in	in	_	_	_	_	_	_	_
6	resting	rest	_	_	_	_	_	_	_
7	PBMCs	pbmc	_	_	_	_	_	_	_
8	infected	infect	_	_	_	_	_	_	_
9	in	in	_	_	_	_	_	_	_
10	vitro	vitro	_	_	_	_	_	_	_
11	with	with	_	_	_	_	_	_	_
12	HIV-1	HIV-1	_	_	_	_	_	_	_
13	was	be	_	_	_	_	_	_	_
14	found	find	_	_	_	_	_	_	_
15	to	to	_	_	_	_	_	_	_
16	be	be	_	_	_	_	_	_	_
17	specifically	specifically	_	_	_	_	_	_	_
18	induced	induce	_	_	_	_	_	_	_
19	by	by	_	_	_	_	_	_	_
20	ligands	ligand	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	the	the	_	_	_	_	_	_	_
23	CDR2-loop	cdr2-loop	_	_	_	_	_	_	_
24	in	in	_	_	_	_	_	_	_
25	domain	domain	_	_	_	_	_	_	_
26	1	1	_	_	_	_	_	_	_
27	(	(	_	_	_	_	_	_	_
28	D1	d1	_	_	_	_	_	_	_
29	)	)	_	_	_	_	_	_	_
30	of	of	_	_	_	_	_	_	_
31	CD4	CD4	_	_	_	_	_	_	_
32	(	(	_	_	_	_	_	_	_
33	virus	virus	_	_	_	_	_	_	_
34	envelope	envelope	_	_	_	_	_	_	_
35	and	and	_	_	_	_	_	_	_
36	anti-CD4	anti-cd4	_	_	_	_	_	_	_
37	monoclonal	monoclonal	_	_	_	_	_	_	_
38	antibodies	antibody	_	_	_	_	_	_	_
39	)	)	_	_	_	_	_	_	_
40	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	contrast	contrast	_	_	_	_	_	_	_
3	,	,	_	_	_	_	_	_	_
4	virus	virus	_	_	_	_	_	_	_
5	reactivation	reactivation	_	_	_	_	_	_	_
6	was	be	_	_	_	_	_	_	_
7	not	not	_	_	_	_	_	_	_
8	observed	observe	_	_	_	_	_	_	_
9	following	follow	_	_	_	_	_	_	_
10	CD4	cd4	_	_	_	_	_	_	_
11	oligomerization	oligomerization	_	_	_	_	_	_	_
12	by	by	_	_	_	_	_	_	_
13	antibodies	antibody	_	_	_	_	_	_	_
14	that	that	_	_	_	_	_	_	_
15	bind	bind	_	_	_	_	_	_	_
16	other	other	_	_	_	_	_	_	_
17	epitopes	epitope	_	_	_	_	_	_	_
18	in	in	_	_	_	_	_	_	_
19	D1	D1	_	_	_	_	_	_	_
20	,	,	_	_	_	_	_	_	_
21	including	include	_	_	_	_	_	_	_
22	the	the	_	_	_	_	_	_	_
23	D1/CDR3-loop	d1/cdr3-loop	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	Finally	finally	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	soluble	soluble	_	_	_	_	_	_	_
4	CD4	cd4	_	_	_	_	_	_	_
5	(	(	_	_	_	_	_	_	_
6	sCD4	scd4	_	_	_	_	_	_	_
7	)	)	_	_	_	_	_	_	_
8	prevented	prevent	_	_	_	_	_	_	_
9	virus	virus	_	_	_	_	_	_	_
10	reactivation	reactivation	_	_	_	_	_	_	_
11	by	by	_	_	_	_	_	_	_
12	D1/CDR2-loop	D1/CDR2-loop	_	_	_	_	_	_	_
13	ligands	ligand	_	_	_	_	_	_	_
14	.	.	_	_	_	_	_	_	_

1	Our	our	_	_	_	_	_	_	_
2	results	result	_	_	_	_	_	_	_
3	indicate	indicate	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	signaling	signaling	_	_	_	_	_	_	_
7	events	event	_	_	_	_	_	_	_
8	initiated	initiate	_	_	_	_	_	_	_
9	in	in	_	_	_	_	_	_	_
10	PBMCs	pbmc	_	_	_	_	_	_	_
11	by	by	_	_	_	_	_	_	_
12	oligomerization	oligomerization	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	CD4	cd4	_	_	_	_	_	_	_
15	at	at	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	D1/CDR2-loop	D1/CDR2-loop	_	_	_	_	_	_	_
18	can	can	_	_	_	_	_	_	_
19	trigger	trigger	_	_	_	_	_	_	_
20	HIV-1	HIV-1	_	_	_	_	_	_	_
21	upregulation	upregulation	_	_	_	_	_	_	_
22	in	in	_	_	_	_	_	_	_
23	infected	infected	_	_	_	_	_	_	_
24	individuals	individual	_	_	_	_	_	_	_
25	.	.	_	_	_	_	_	_	_

